Technologies & Platforms
WuXi Biologics is committed to providing open-access technology platforms so that any company anywhere can efficiently and cost effectively bring new medicines to patients worldwide. Our technology platforms span the entire discovery to manufacturing spectrum.
WuXi Biologics offers five advanced platforms for discovery of antibody-based therapeutics and we leverage these platforms individually or combined to find the ideal therapeutic antibody.
WuXiBody™ Bispecific Antibody Platform
WuXiBody™ is an innovative, proprietary technology platform developed by WuXi Biologics for the expanding field of bispecific antibodies. Based on novel engineering, the platform can expedite the drug development process by 6-18 months and significantly reduce cost-of-goods. The WuXiBody™ platform enables almost any mAb sequence pair to be assembled into the bispecific construct and its unique structural flexibility makes the platform convenient to build various formats with different valency (e.g., 2, 3 or 4 binding sites).
WuXian Express for Custom Protein Production
Our unique Wuxian Express custom protein production platform for generation of R&D-grade proteins and antibodies is designed to fill the gap between transient production and traditional stable pool methodologies. Compared to transient production, Wuxian Express delivers significantly more material, yet only adds 1 week to the overall timeline. Compared to the traditional stable pool production, Wuxian Express is 6 weeks faster and thus offers significant time and cost savings to obtain the same production scale.
WuXia Cell Line Development
Our proprietary CHO K1 cell line development platform was designed to provide high titer production cell lines while also keep drug development costs low and to allow ultimate flexibility for cell line use in the production of protein therapeutics.
WuXiUP Continuous Process Platform
The breakthrough WuXiUP process couples continuous perfusion cell culture utilizing Repligen XCell™ ATF System technology with continuous direct product capture column chromatography. This highly efficient system enables a similar purification yield to traditional purification processes. With this technology, a 1,000L disposable bioreactor can produce more than 30 kg of mAb per batch and approximately 500 kg per year, thus providing similar productivity as traditional 10,000-20,000 L stainless steel bioreactors. This process platform can expedite product development and significantly reduce the cost of goods for a commercial product.
Taking advantage of the advancements in disposable manufacturing technologies and in response to market demands for commercial manufacturing operations that reduce risk, costs and offer greater flexibility and scalability for product supply, WuXi Biologics designed and built multiple state-of-the-art manufacturing facilities for clinical and commercial supply of biological therapeutics.
Cell Culture Development and Manufacturing
WuXi Biologics utilizes three different cell culture technologies that can be used as a standard platform process or customized to meet your protein production requirements.
Fed-batch using single-use disposable bioreactors (up to 2,000 L)
Concentrated Fed-batch approach to deliver higher yields per run
WuXiUP Continuous Biomanufacturing Platform with Ultra-high Productivity
Over 115 different cell-based functional/potency assays have been developed for our clients by our 70+ team of bioassay experts. Included are patent pending ADCC and CDC assays.